Ferring Pharmaceuticals Showcases Commitment to Advancing Fertility Care at 2024 ASRM Congress
Ferring Pharmaceuticals will present new data from four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and virtually. The presentations include two oral and two poster sessions, reflecting Ferring’s dedication to advancing fertility care through a multifaceted approach.
“We are excited to share important research and insights that healthcare professionals can apply in their practice,” said Sasmira Lalwani, Senior Medical Director of Reproductive Medicine at Ferring. “Our findings underscore our commitment to supporting diverse family-building needs, as we recognize that there isn’t a ‘one-size-fits-all’ approach to fertility care.”
Abstracts Overview
The four abstracts cover various critical topics in reproductive medicine:
- Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions
- Poster #24
- EMBARGOED UNTIL: October 21, 10:45 – 11:00 a.m. MDT
- Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey
- Oral Presentation #184
- EMBARGOED UNTIL: October 22, 11:45 – 11:56 a.m. MDT
- Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis
- Oral Presentation #154
- EMBARGOED UNTIL: October 22, 10:56 – 11:07 a.m. MDT
- Assessing the Impact of an eLearning Platform for Educating Fertility Professionals
- Poster #652
- EMBARGOED UNTIL: October 23, 11:30 – 11:45 a.m. MDT
“For over 50 years, Ferring has been committed to helping more people become parents by addressing the evolving needs within reproductive medicine,” stated David Powley, Vice President of Reproductive Medicine and Operations at Ferring. “ASRM is a vital opportunity to discuss our contributions, investment in reproductive health, and collaborations with healthcare professionals to enhance patient experience and outcomes.”
In addition to the data presentations, Ferring will host a discussion titled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” on October 21 at 10:05 a.m. MDT. This moderated panel will explore legislative and policy advances aimed at expanding access to family-building care and infertility treatment.
Panelists include:
- Serena H. Chen, MD – Reproductive Endocrinologist, Director of Advocacy at CCRM NJ – IRMS Reproductive Medicine
- Michael A. Thomas, MD – Professor and Chair, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine
- Sean B. Tipton, MA – Chief Advocacy & Policy Officer, American Society for Reproductive Medicine
Ferring’s presence at the ASRM Congress reinforces its commitment to enhancing fertility care and advocating for patients seeking family-building solutions.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
